Immunotherapy: Precision Medicine in Action

Immunotherapy: Precision Medicine in Action The importance of keeping the promise and potential of immunotherapy alive

The first cancer immunotherapy was approved in 2011; today, there are more than 70 such drugs in the clinical pipeline. By 2020, the cancer treatment industry is expected to achieve $16.55 billion dollars in revenue. Read our policy brief to learn more about milestones in cancer immunotherapy.

One of the most recent examples of individualized or precision medicine is cancer immunotherapy. This approach of making cancer cells visible to the patient’s own immune system, allowing it to take action against cancer, has led to numerous success stories for those with various cancers. What do leaders predict for the future of immunotherapy? How are academia and drug companies working together to move this field forward? Learn more from a panel of health care industry leaders, including those from the Bloomberg~Kimmel Institute for Cancer Immunotherapy, patient advocacy groups and the pharmaceutical industry.

Wednesday, March 8, from 9 to 10:30 a.m.
National Press Club
529 14th St. NW, 13th Floor, Fourth Estate Room, Washington, DC 20045
Registration is free.

Johns Hopkins inHealth: On the Road to Precision Medicine

Johns Hopkins inHealth kicks off the Hopkins On The Road health care leader series, where experts discuss the importance of precision medicine within the field of immunotherapy.


Laurie McGingley
Health and medical reporter, The Washington Post

Margaret Anderson
Executive Director, FasterCures

Roy Baynes, MD, PhD
Senior Vice President and Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

Glenn Dranoff, MD
Global Head of Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

Elizabeth Jaffee, MD
The Dana and Albert "Cubby" Broccoli Professor of Oncology
Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Co-Director, Skip Viragh Center for Pancreas Cancer
Associate Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
Co-Chair, Blue Ribbon Panel, Vice President Joe Biden’s Cancer Moonshot Initiative

William Nelson, MD, PhD
Marion I. Knott Director and Professor of Oncology and Director of The Sidney Kimmel Comprehensive Cancer Center